3 documents found, page 1 of 1
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis
Ørnbjerg, Lykke Midtbøll; Brahe, Cecilie Heegaard; Linde, Louise; Jacobsson, Lennart; Nissen, Michael J.; Kristianslund, Eirik Klami; Santos, Maria JoséFunding Information: This work was supported by Novartis. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit. Publisher Copyright: © 2024 The Authors; Objective: To investigate real-world retention and remission rates in PsA patients initiating a 2nd or 3rd TNFi and the association with reason for discontinuation from the previous TNFi-treatment....
Corrigendum to ‘Predictors of ASDAS-CRP inactive disease in axial spondyloarthr...
Ørnbjerg, Lykke M.; Linde, Louise; Georgiadis, Stylianos; Rasmussen, Simon H.; Lindström, Ulf; Askling, Johan; Michelsen, Brigitte; Giuseppe, Daniela DiThe authors regret that the following incorrect values have been published in the original paper: In the abstract: Line 11-12: “age, per year: 0.97 (0.97-0.98)” should be “age, per year: 0.98 (0.97-0.99)” Line 12: “men vs. women: 1.88 (1.60-2.22)” should be “men vs. women: 1.79 (1.51-2.12)” Line 12: “current vs. non-smoking: 0.76 (0.63-0.91)” should be “current vs. non-smoking: 0.72 (0.59-0.87)” Line 12-13: “HL...
Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during trea...
Ørnbjerg, Lykke M.; Linde, Louise; Georgiadis, Stylianos; Rasmussen, Simon H.; Lindström, Ulf; Askling, Johan; Michelsen, Brigitte; Giuseppe, Daniela DiFunding Information: LMØ, LL, SG and SHR: research grants from Novartis; UL: none; DDG none; JKW: consultant of AbbVie, Amgen, Celgene, Eli Lilly and Novartis; BG: research grants from Pfizer, Abbvie and BMS; LP: consultant of Novartis Finland, UCB Pharma, Pfizer, Sanofi, BMS, AbbVie, Amgen, Celgene, Eli Lilly, Boehringer-Ingelheim, Mylan; KL: consulting and/or speaking fees from Amgen, Johnson and Johnson and ...